Abstract
Systemic fungal infections pose a significant risk to patients following allogeneic hematopoietic cell transplantation (alloHCT). Voriconazole (Vfend, Pfizer) is an oral second-generation triazole antifungal agent that offers a broad spectrum of coverage against fungal species and is frequently utilized in the post-HCT setting. Herein, we describe 5 patients who were initially believed to be experiencing a flare of cutaneous chronic graft-versus-host disease (cGVHD), but who were actually exhibiting phototoxicity caused by voriconazole. A high index of suspicion for this adverse reaction in the post-alloHCT setting will prevent misdiagnosis and avoid inappropriate therapy for cGVHD.
Publication types
-
Case Reports
-
Research Support, N.I.H., Intramural
MeSH terms
-
Adolescent
-
Adult
-
Antifungal Agents / adverse effects*
-
Antifungal Agents / therapeutic use
-
Child
-
Dermatitis, Phototoxic / diagnosis*
-
Dermatitis, Phototoxic / etiology
-
Diagnosis, Differential
-
Female
-
Graft vs Host Disease / chemically induced
-
Graft vs Host Disease / diagnosis*
-
Graft vs Host Disease / etiology
-
Graft vs Host Disease / immunology
-
Hematopoietic Stem Cell Transplantation / adverse effects*
-
Humans
-
Male
-
Middle Aged
-
Mycoses / drug therapy
-
Pyrimidines / adverse effects*
-
Pyrimidines / therapeutic use
-
Retrospective Studies
-
Triazoles / adverse effects*
-
Triazoles / therapeutic use
-
Voriconazole
Substances
-
Antifungal Agents
-
Pyrimidines
-
Triazoles
-
Voriconazole